HER2 and HLA-A*02 Dual CAR-T Cells Utilize LOH in a NOT Logic Gate to Address On-Target Off-Tumor Toxicity

iCAR paper graphic 12-20-23

ImmPACT Bio is pleased to announce the publication of their work in the Journal of ImmunoTherapy of Cancer regarding NOT logic gated CAR T cells for limiting on-target off-tumor toxicity titled, “HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity”. This work demonstrates that inhibitory CAR targeting an antigen present exclusively on healthy tissue can protect non-malignant cells from being killed when the conventional tumor antigen is present on both healthy and malignant cells.

Click here for the publication: HER2 and HLA-A* 02 Dual CAR-T Cells Utilize LOH in a NOT Logic Gate to Address On-Target Off-Tumor Toxicity

You are about to leave Immpact Bio's website to an external website.

Immpact Bio is not responsible for the accuracy or content of information contained on external/third-party websites.

You are about to leave Immpact Bio's website to an external website.

Immpact Bio is not responsible for the accuracy or content of information contained on external/third-party websites.

You are about to leave Immpact Bio's website to an external website.

Immpact Bio is not responsible for the accuracy or content of information contained on external/third-party websites.

You are about to leave Immpact Bio's website to an external website.

Immpact Bio is not responsible for the accuracy or content of information contained on external/third-party websites.

ImmPACT Bio is now part of Lyell Immunopharma

If you have a question about a clinical trial, please contact us at info@immpact-bio.com